ASPREE Project News
New polygenic risk score for melanoma
New genomic tool advances melanoma risk prediction in older Australians Researchers have developed a new...
Effect of aspirin on long-term management of depression
Analysis shows aspirin’s potential adverse effect on mood in older adults with pre-existing depression ...
ALSOP reveals widespread use of complementary medicine in older Australians
First comprehensive data on complementary medicine use by community-dwelling older Australians Almost 75% of...
Meet the team: Introducing a US ASPREE investigator
Above: Prof Mike Ernst is a US based investigator to the ASPREE project. Meet Professor Mike Ernst Michael E....
Aspirin and major gastrointestinal bleeding risk
New analysis identifies potential risk of major GI bleeding in older adults A closer analysis of data from the...
Update: ASPREE-XT study visits and COVID-19
Important information about ASPREE-XT study visits and COVID-19 The ASPREE-XT study team continues to adapt...
Observational statin study in ASPREE participants
Statins may prevent heart attacks and strokes but may not prolong life free of disability PRESS RELEASE...
Low-dose aspirin and depression
ASPREE-D sub-study finds daily aspirin not protective against late-life depression PRESS RELEASE: 4th June 2020...
Aspirin and cognitive decline
Daily low-dose aspirin does not prevent cognitive decline in healthy older adults PRESS RELEASE: 1st...
ASPREE-XT 2019 in summary
A year of major achievements for long-term aspirin study This year, we welcomed a mid-year announcement that...